Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma.
Kazia Therapeutics stock last closed at $0.28, down 5.69% from the previous day, and has decreased 77.97% in one year. It has underperformed other stocks in the Biotechnology industry by 0.6 percentage points. Kazia Therapeutics stock is currently +50.8% from its 52-week low of $0.19, and -79.71% from its 52-week high of $1.39.
There are currently 263.62M shares of KZIA outstanding. The market cap of KZIA is $7.43M. In the last 24 hours, 412,753 KZIA shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy KZIA stock.
We believe that eToro is the best brokerage. Here's why:
Get $10 towards your purchase of shares by signing up for an account with eToro today.
Open eToro AccountNow that you've picked the right brokerage, you'll need to fill out some personal details so you are able to invest in KZIA today.
Now that you have created your account on app for investing, you can securely and quickly fund your account:
Watch this video walkthrough for more details transferring money into your new brokerage account.
After you have identified the best place to buy Kazia Therapeutics stock, it's critical to analyze their stock before you invest, so you actually understand the risk as well as the opportunity.
WallStreetZen was built to help everyday investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on KZIA's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge KZIA's intrinsic value.
Using relative valuations methods:
You can do more valuation research on KZIA's stock here.
Last year, KZIA revenue was $15.13k. During the past 5 year, KZIA's revenue has grown by -65.97% per year. This was slower than the Biotechnology industry average of 29.57%.
Dig into KZIA's earnings and revenue performance here.
In the past year, insiders at KZIA have not bought or sold any shares.
Dig into more about who owns KZIA shares here.
No, Kazia Therapeutics doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
There are two primary options:
Hit the Open button and your broker will place your order.
If you require additional help with investing in stocks on eToro, watch the helpful video below:
Now that you own some KZIA stock, you'll want to stay up-to-date on your new shares.
Start a watchlist to get notified of important updates regarding your KZIA stock.
To summarize, here are the 6 steps you need to take to buy Kazia Therapeutics stock right now:
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your investment in Kazia Therapeutics, add KZIA to your watchlist below.